New trial
Phase 2 Tarlatamab Trial: DLL3 and CD3-directed bispecific antibody
- Trial ID
- NCT06745323 on ClinicalTrials.gov
- Cancer type
- SCLC
- Location
- 34 Locations
- Published in
- New in Oncology - June 16, 2025
This open-label randomized study evaluates Tarlatamab dosing regimens in patients with relapsed or refractory small cell lung cancer. Conducted at global centers by Amgen, it examines the antitumor activity of this novel bispecific antibody targeting DLL3 and CD3.
More in small cell lung cancer
-
New trial · Oct 15, 2026 · NCT07625644
Phase 3 BrenDeLL-Lung01 tests DLL3-targeted BL-M14D1 plus atezolizumab in first-line extensive-stage SCLC -
New trial · Oct 1, 2026 · NCT07339059
Phase 2 sacituzumab govitecan TROP2-directed SN-38 ADC + PD-L1 blockade maintenance in ES-SCLC -
New trial · Sep 10, 2026 · NCT07778316
Phase 3 tarlatamab (Amgen) DLL3×CD3 bispecific T‑cell engager compares SC vs IV dosing -
New trial · Sep 3, 2026 · NCT07365241
Phase 3 ABBV-706 SEZ6-targeted topo-1 ADC vs chemotherapy in R/R SCLC -
Trial result · Aug 13, 2026
LIPI strongly stratifies survival in ES-SCLC but does not predict chemo-IO benefit